Insider Selling: Corcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sells 5,000 Shares of Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) insider Joseph Douglas Lyon sold 5,000 shares of Corcept Therapeutics stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $78.04, for a total transaction of $390,200.00. Following the transaction, the insider now owns 9,009 shares in the company, valued at $703,062.36. The trade was a 35.69% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Joseph Douglas Lyon also recently made the following trade(s):

• On Monday, March 24th, Joseph Douglas Lyon sold 421 shares of Corcept Therapeutics stock. The stock was sold at an average price of $60.58, for a total value of $25,504.18.

Corcept Therapeutics Stock Performance

Shares of NASDAQ CORT traded up $0.47 during mid-day trading on Wednesday, hitting $69.98. The company had a trading volume of 1,141,760 shares, compared to its average volume of 1,146,915. The firm has a market cap of $7.42 billion, a P/E ratio of 55.54 and a beta of 0.22. Corcept Therapeutics Incorporated has a 12 month low of $28.04 and a 12 month high of $117.33. The business's 50-day simple moving average is $73.38 and its 200-day simple moving average is $63.62. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.70 and a quick ratio of 3.64.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The biotechnology company reported $0.17 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.17. Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The firm had revenue of $157.21 million during the quarter, compared to the consensus estimate of $177.93 million. During the same quarter in the previous year, the company posted $0.25 EPS. The business's revenue for the quarter was up 7.1% compared to the same quarter last year. As a group, analysts predict that Corcept Therapeutics Incorporated will post 1.36 earnings per share for the current fiscal year.

Institutional Trading of Corcept Therapeutics

A number of large investors have recently made changes to their positions in CORT. Focus Partners Wealth increased its holdings in Corcept Therapeutics by 0.5% during the 1st quarter. Focus Partners Wealth now owns 33,243 shares of the biotechnology company's stock worth $3,797,000 after purchasing an additional 170 shares in the last quarter. Brooklyn Investment Group grew its stake in shares of Corcept Therapeutics by 99.5% in the first quarter. Brooklyn Investment Group now owns 373 shares of the biotechnology company's stock valued at $43,000 after buying an additional 186 shares in the last quarter. Black Diamond Financial LLC boosted its stake in shares of Corcept Therapeutics by 4.0% during the 4th quarter. Black Diamond Financial LLC now owns 5,200 shares of the biotechnology company's stock worth $262,000 after acquiring an additional 200 shares during the period. Wealth Enhancement Advisory Services LLC boosted its position in Corcept Therapeutics by 3.0% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 7,954 shares of the biotechnology company's stock worth $909,000 after purchasing an additional 230 shares during the period. Finally, Quadrant Capital Group LLC boosted its holdings in shares of Corcept Therapeutics by 9.5% during the 4th quarter. Quadrant Capital Group LLC now owns 2,969 shares of the biotechnology company's stock worth $150,000 after buying an additional 257 shares during the period. Institutional investors own 93.61% of the company's stock.

Analysts Set New Price Targets

Several brokerages have issued reports on CORT. Wall Street Zen cut Corcept Therapeutics from a "buy" rating to a "hold" rating in a research note on Wednesday, May 14th. Truist Financial set a $135.00 price target on Corcept Therapeutics in a report on Tuesday, May 6th. Piper Sandler lifted their price target on Corcept Therapeutics from $128.00 to $131.00 and gave the company an "overweight" rating in a research report on Thursday, April 3rd. Canaccord Genuity Group lifted their price target on shares of Corcept Therapeutics from $130.00 to $142.00 and gave the stock a "buy" rating in a research report on Tuesday, April 1st. Finally, HC Wainwright dropped their price target on Corcept Therapeutics from $150.00 to $145.00 and set a "buy" rating on the stock in a research note on Tuesday, May 6th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $138.25.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.